

Novugen Oncology Manufacturing Facility in Malaysia Receives Approval from UAE MoHAP | May 2025

We are proud to share that our **Novugen Oncology manufacturing facility in Bandar Enstek, Negeri Sembilan, Malaysia** received approval from the **Ministry of Health & Prevention (MoHAP) of the United Arab Emirates (UAE)** in May 2025.

This achievement follows the approval of our Novugen Pharma manufacturing facility by MoHAP last year and marks our first regulatory endorsement for the Oncology division beyond PIC/S and USFDA accreditations. It reflects our commitment to global quality standards, supported by OEB Level 5 technology and state-of-the-art high-containment research capabilities that exemplify innovation and excellence.

With registration processes already underway, we are well-positioned to drive greater impact for both Novugen and Malaysia on the global pharmaceutical landscape. This includes expanding access to high-quality oncology products across the MENA markets while strengthening our footprint in the region.

This milestone was made possible through the collaborative efforts of our team at Novugen. Together, we will continue striving for excellence as we shape the future of Novugen and elevate Malaysia's role in global healthcare.